Prot# CTCH346A2211E1: A Long-Term Extension to a Rndmzd, Dble-Blind, Placebo-Controlled, Stratified, Parallel-Group, Mltcntr, Dose-Ranging Study Evaluating 4 Oral Doses of TCH346(1.0,2.5,7.5 & 15mg)Admin 1x Daily in Ptnts w/Amyotrophic Lateral Sclerosis

Project: Research project

Project Details

StatusFinished
Effective start/end date10/1/0410/1/11

Funding

  • Novartis Pharmaceuticals Corporation (CTCH346A2211E1)